Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion type Assertion NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_head.
- NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion description "[As hyperactivation of the PI3K/AKT/mTOR pathway is frequently observed in gliomas, the combined use of ER? agonists may become a feasible therapy option to overcome chemoresistance to TMZ.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_provenance.
- NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion evidence source_evidence_literature NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_provenance.
- NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion SIO_000772 25351348 NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_provenance.
- NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion wasDerivedFrom befree-2016 NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_provenance.
- NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_assertion wasGeneratedBy ECO_0000203 NP1233223.RAWCsKhuaxkheXdoPrDcqFZiIS5qHt_uTri5kpFLfbRzI130_provenance.